July 1, 2008 Research Projects by Attending Physicians Affiliated with Inova Fairfax Hospital Cancer Center
This list of open research trials is meant to be a general information resource only. This information is updated on a bimonthly basis. It should not replace or supercede information given by the patient's physician. These studies may close without warning. In addition to the consent forms for these studies, additional general disease information can be found on www.cancer.gov.
General (public) information about the Children's Oncology Group (COG) is on their site: www.childrensoncologygroup.org. General information regarding clinical trials for patients can be found on the Inova Research Guide for Patients and Families. The U.S. government has a clinical trials Web site that might also prove a helpful resource for patients. It allows people to look for trials in specific therapeutic areas and can be viewed at http://www.clinicaltrials.gov/ct/action/ . The National Cancer Institute (NCI) also has trial search engines and information on clinical trials at http://www.cancer.gov/clinical_trials/ and http://www.cancertrialshelp.org/patientsCaregivers/patientsCaregivers.jsp
The contact person for all these studies is: Jay Greenberg, MD, 703-876-9111. The study coordinator is Keary Jane’t, 702- 280-3856. The specific protocols are:Disease: Pediatric Bone Tumors
P9851
Biology and Banking **to enroll on front-line therapeutic study, all subjects must first be registered on this study
Open
AOST0331
EURAMOS 1: Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies and Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy **NCI DRUG Pegylated Interferon alfa 2b
AEWS0331
European Ewing Tumor Working Initiative of National Groups, Ewing Tumor Studies 1999 – Metastatic Pulmonary ONLY
Disease: Pediatric Soft Tissue Sarcoma
D9902
A COG Protocol for Collecting and Banking Soft Tissue Sarcoma Specimens **to enroll on front-line therapeutic study, all subjects must first be registered on this study
ARST0321
Phase II Study of Sulindac and Tamoxifen in Patients with Desmoid Tumors that are Recurrent or Not Amendable to Standard Therapy
ARST0331
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide with or without Radiation Therapy for Patients with Newly Dx’d Low Risk Embryonal/Botryoid/Spindle Cell Rhabdomyosarcoma
ARST0531
Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) vs. (VAC) Alternating with Vincristine and Irinotecan for Patients with Intermediate Risk Rhabdomyosarcoma
Disease: Pediatric Brain Tumors
ACNS02B3
A COG Protocol for Collecting and Banking Pediatric Brain Tumors – ALL Tumors
ACNS0221
Phase II Study of Conformal Radiotherapy in Patients with Low Grade Glioma
ACNS0331
A Study Evaluation limited Target Volume Boost Irradiation and Reduced Dose Crainospinal Radiotherapy and Chemotherapy with Newly Diagnosed Standard Risk Medulloblastoma
Disease: Pediatric Germ Cell Study # Study Title Status AGCT0132 A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors Open Disease: Pediatric Acute Lymphoblastic Leukemia
AGCT0132
A Phase III Study of Reduced Therapy in the Treatment of Children with Low and Intermediate Risk Extracranial Germ Cell Tumors
AALLO2P2
Treatment of Late Isolated Extramedullary Relapse From ALL Initial CR1>/= 18 months
AALL03N1
Understanding the Role of Adherence in the Ethnic Differences in Survival After Childhood ALL
AALL03B1
Classification of ALL
Disease: Pediatric Non-Hodgkin Lymphoma
ANHL0131
A Phase III Trial of the Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma with Standard APO vs Consolidation with a Regimen Including Vinblastine
A Pilot Study to Determine the Toxicity of the Addition of Rituximab to the Induction and Consolidation Phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Dx’d Advanced B-Cell Leukemia/Lymphoma Treated with LMB/FAB Therapy
Other: Solid Tumors
PHOA
In-House Myeloablative Chemotherapy with Stem Cell Rescue for High Risk Pediatric Solid Tumors
Disease: Pediatric Hodgkin Disease
AHOD03P1
Treatment for Children with Newly Dx’d Low Stage LPHD (Lymphocyte Predominant HD)
AHOD0431
A Phase III Study of the Treatment of Children with Newly Dx’d Low Risk HD
Disease: Pediatric Neuroblastoma
ANBL00B1
Neuroblastoma Biology Protocol
ANBL00P3
A Phase III Randomized Trial of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated with Chemotherapy and Prednisone
ANBL0032
A Phase III Randomized Study of Chimeric Antibody 14.18 in High Risk Neuroblastoma Following Myeloablative Therapy and Autologous Stem Cell Rescue
ANBL00P2
Perinatal Neuroblastoma
In-House POG 9640: Treatment of Patients with High Risk Neuroblastoma Using Two Cycles of Marrow Ablative Chemotherapy Followed By Rescue with Peripheral Blood Stem Cells
Disease: Pediatric Rare Tumors
ABTR01B1
A COG Protocol for Collecting and Banking Pediatric Rare Tumors
Disease: Hepatoblastoma
9346
Liver Tumors Biology and Banking
Disease: Wilms
AREN03B2
Renal Tumors Classification, Biology and Banking Study
AREN0533
Treatment of Newly Dx’d Higher Risk Favorable Histology Wilms Tumor
AREN0532
Treatment for Very Low, Low and Standard Risk Favorable Histology Wilms Tumor
Disease: Nasopharyngeal
ARAR0331
Treatment of Childhood Nasopharyngeal Carcinoma
Disease: Late Effects
ATLE03N1
Late Effects
AALL06N1
Neuro-Cognitive Function in Children Treated for ALL